Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $37.9286.

A number of equities research analysts have weighed in on GMAB shares. Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Jefferies Financial Group started coverage on Genmab A/S in a report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 target price for the company. Weiss Ratings downgraded Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. HC Wainwright lowered their target price on Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a report on Thursday, April 30th. Finally, BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd.

Genmab A/S Trading Up 1.2%

Shares of GMAB stock opened at $27.04 on Friday. The company has a market cap of $16.86 billion, a P/E ratio of 20.49, a PEG ratio of 1.59 and a beta of 0.86. The stock has a 50 day simple moving average of $27.00 and a two-hundred day simple moving average of $29.64. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. Genmab A/S has a fifty-two week low of $20.23 and a fifty-two week high of $35.43.

Institutional Investors Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently modified their holdings of the company. CIBC Private Wealth Group LLC increased its holdings in shares of Genmab A/S by 291.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after acquiring an additional 616 shares in the last quarter. Osaic Holdings Inc. boosted its position in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the last quarter. V Square Quantitative Management LLC purchased a new position in Genmab A/S in the first quarter worth $34,000. NewEdge Advisors LLC raised its stake in shares of Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after buying an additional 1,143 shares during the period. Finally, Brown Brothers Harriman & Co. raised its stake in shares of Genmab A/S by 143.4% in the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after buying an additional 780 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.